Functionality of the immune system in patients with chronic hepatitis C: trial by superinfections and vaccinations

References

• Rook GA, Stanford JL. Give us this day our daily germs. Immunol. Today19(3), 113–116 (1998).
   PubMedGoogle Scholar
• Kim SK, Cornberg M, Wang XZ, Chen HD, Selin LK, Welsh RM. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J. Exp. Med.201(4), 523–533 (2005).
   PubMed Web of Science ®Google Scholar
• Welsh RM, Kim SK, Cornberg M, Clute SC, Selin LK, Naumov YN. The privacy of T cell memory to viruses. Curr. Top. Microbiol. Immunol.311, 117–153 (2006).
   PubMed Web of Science ®Google Scholar
• Ostler T, Pircher H, Ehl S. “Bystander” recruitment of systemic memory T cells delays the immune response to respiratory virus infection. Eur. J. Immunol.33(7), 1839–1848 (2003).
   PubMed Web of Science ®Google Scholar
• Naniche D, Yeh A, Eto D, Manchester M, Friedman RM, Oldstone MB. Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of α/β interferon production. J. Virol.74(16), 7478–7484 (2000).
   PubMedGoogle Scholar
• Moss WJ, Ota MO, Griffin DE. Measles: immune suppression and immune responses. Int. J. Biochem. Cell Biol.36(8), 1380–1385 (2004).
   PubMedGoogle Scholar
• Desai HN, Strashoon J, Wesley A. Cell-mediated immunity in measles using the leucocyte migration test. Int. Arch. Allergy Appl. Immunol.57(4), 312–316 (1978).
   PubMedGoogle Scholar
• Khan N, Hislop A, Gudgeon N et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J. Immunol.173(12), 7481–7489 (2004).
   PubMed Web of Science ®Google Scholar
• Isaguliants MG. Hepatitis C virus clearance: the enigma of failure despite an impeccable survival strategy. Curr. Pharm. Biotechnol.4(3), 169–183 (2003).
   PubMedGoogle Scholar
• Pal S, Sullivan DG, Kim S et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology130(4), 1107–1116 (2006).
   PubMedGoogle Scholar
• Kondo Y, Sung VM, Machida K, Liu M, Lai MM. Hepatitis C virus infects T cells and affects interferon-γ signaling in T cell lines. Virology361(1), 161–173 (2007).
   PubMedGoogle Scholar
• Praditpornsilpa K, Eiam-Ong S, Sitprija V. Hepatitis virus and kidney. Singapore Med. J.37(6), 639–644 (1996).
   PubMedGoogle Scholar
• Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation92(9), 2519–2525 (1995).
   PubMed Web of Science ®Google Scholar
• Kanazawa H, Yoshikawa J. Alterations in T-lymphocyte subsets in the airways of asthmatic patients with active hepatitis C virus infection. Respiration73(3), 318–323 (2006).
   PubMedGoogle Scholar
• Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J. Viral Hepat.10(2), 81–86 (2003).
   PubMed Web of Science ®Google Scholar
• Berk DR, Mallory SB, Keeffe EB, Ahmed A. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin. Gastroenterol. Hepatol.5(2), 142–151 (2007).
   PubMedGoogle Scholar
• Weng WK, Levy S. Hepatitis C virus (HCV) and lymphomagenesis. Leuk. Lymphoma44(7), 1113–1120 (2003).
   PubMed Web of Science ®Google Scholar
• Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J. Infect. Dis.192(3), 497–503 (2005).
   PubMed Web of Science ®Google Scholar
• Kanto T, Inoue M, Miyazaki M et al. Impaired function of dendritic cells circulating in patients infected with hepatitis C virus who have persistently normal alanine aminotransferase levels. Intervirology49(1–2), 58–63 (2006).
   PubMedGoogle Scholar
• Matsui M, Moriya O, Abdel-Aziz N, Matsuura Y, Miyamura T, Akatsuka T. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine21(3–4), 211–220 (2002).
   PubMed Web of Science ®Google Scholar
• Sapp M, Engelmayer J, Larsson M, Granelli-Piperno A, Steinman R, Bhardwaj N. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol. Lett.66(1–3), 121–128 (1999).
   PubMed Web of Science ®Google Scholar
• Larsson M, Babcock E, Grakoui A et al. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J. Virol.78(12), 6151–6161 (2004).
   PubMed Web of Science ®Google Scholar
• Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood97(10), 3171–3176 (2001).
   PubMed Web of Science ®Google Scholar
• Dolganiuc A, Kodys K, Kopasz A et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J. Immunol.170(11), 5615–5624 (2003).
   PubMedGoogle Scholar
• Sarobe P, Lasarte JJ, Zabaleta A et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J. Virol.77(20), 10862–10871 (2003).
   PubMed Web of Science ®Google Scholar
• Anthony DD, Yonkers NL, Post AB et al. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J. Immunol.172(8), 4907–4916 (2004).
   PubMed Web of Science ®Google Scholar
• Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology120(2), 512–524 (2001).
   PubMed Web of Science ®Google Scholar
• Kanto T, Hayashi N, Takehara T et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J. Immunol.162(9), 5584–5591 (1999).
   PubMed Web of Science ®Google Scholar
• Szabo G, Dolganiuc A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology210(2–4), 237–247 (2005).
   PubMedGoogle Scholar
• Kakumu S, Okumura A, Ishikawa T, Iwata K, Yano M, Yoshioka K. Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection. Clin. Exp. Immunol.108(1), 138–143 (1997).
   PubMedGoogle Scholar
• Sarobe P, Lasarte JJ, Casares N et al. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J. Virol.76(10), 5062–5070 (2002).
   PubMed Web of Science ®Google Scholar
• Murakami H, Akbar SM, Matsui H, Horiike N, Onji M. Decreased interferon-α production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C. Clin. Exp. Immunol.137(3), 559–565 (2004).
   PubMedGoogle Scholar
• Morita K, Fukuda Y, Nakano I, Katano Y, Hayakawa T. Peripheral lymphocyte subsets vary with stage of hepatitis C virus-associated liver disease. Hepatogastroenterology52(66), 1803–1808 (2005).
   PubMedGoogle Scholar
• Rosa D, Saletti G, De Gregorio E et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc. Natl Acad. Sci. USA102(51), 18544–18549 (2005).
   PubMed Web of Science ®Google Scholar
• Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol.75(13), 6209–6211 (2001).
   PubMed Web of Science ®Google Scholar
• Antonaci S, Piazzolla G, Napoli N, Vella FS, Fiore G, Schiraldi O. Relationship between T lymphocyte responsiveness and T-helper1/T-helper2 type cytokine release in chronic hepatitis C: a critical reappraisal. Microbios106(415), 203–212 (2001).
   PubMedGoogle Scholar
• Semmo N, Day CL, Ward SM et al. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology41(5), 1019–1028 (2005).
   PubMedGoogle Scholar
• Morita K, Fukuda Y, Nakano I, Katano Y, Hayakawa T. Peripheral lymphocyte subsets vary with stage of hepatitis C virus-associated liver disease. Hepatogastroenterology52(66), 1803–1808 (2005).
   PubMedGoogle Scholar
• Mondelli MU, Barnaba V. Viral and host immune regulatory mechanisms in hepatitis C virus infection. Eur. J. Gastroenterol. Hepatol.18(4), 327–331 (2006).
   PubMedGoogle Scholar
• Racanelli V, Rehermann B. Hepatitis C virus infection: when silence is deception. Trends Immunol.24(8), 456–464 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrari C. T and B cells in hepatitis C virus control: what they do and when they fail. Gastroenterology132(2), 801–805 (2007).
   PubMedGoogle Scholar
• Kaplan DE, Sugimoto K, Newton K et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology132(2), 654–666 (2007).
   PubMed Web of Science ®Google Scholar
• Valdez H, Anthony D, Farukhi F et al. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS14(15), 2239–46 (200).
   Google Scholar
• Rosen HR, Miner C, Sasaki AW et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology35(1), 190–198 (2002).
   PubMed Web of Science ®Google Scholar
• England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect. Dis.6(2), 83–90 (2006).
   PubMed Web of Science ®Google Scholar
• Al-Harthi L, Voris J, Du W et al. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J. Infect. Dis.193(9), 1202–1210 (2006).
   PubMedGoogle Scholar
• Graham CS, Koziel MJ. Why should hepatitis C affect immune reconstitution in HIV-1-infected patients? Lancet356(9245), 1865–1866 (2000).
   PubMed Web of Science ®Google Scholar
• Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet356(9244), 1800–1805 (2000).
   PubMed Web of Science ®Google Scholar
• Carlos Martin J, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J, Soriano V. Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin. Trials5(3), 125–131 (2004).
   PubMed Web of Science ®Google Scholar
• Antonucci G, Girardi E, Cozzi-Lepri A et al; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin. Infect. Dis.40(12), E101–E109 (2005).
   Google Scholar
• Nunez M, Soriano V. Current concepts in the management and treatment of hepatitis C in HIV-infected patients. Ann. Hepatol.4(3), 151–160 (2005).
   PubMedGoogle Scholar
• Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES; Hemophilia Growth and Development Study. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J. Infect. Dis.191(1), 4–10 (2005).
   PubMedGoogle Scholar
• Sagnelli E, Coppola N, Messina V et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology36(5), 1285–1291 (2002).
   PubMed Web of Science ®Google Scholar
• Gaeta GB, Stornaiuolo G, Precone DF et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J. Hepatol.39(6), 1036–1041 (2003).
   PubMed Web of Science ®Google Scholar
• Wietzke P, Schott P, Braun F, Mihm S, Ramadori G. Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver19(4), 348–353 (1999).
   PubMedGoogle Scholar
• Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am. J. Gastroenterol.95(10), 2978–2980 (2000).
   PubMed Web of Science ®Google Scholar
• Gruener NH, Jung MC, Ulsenheimer A et al. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J. Hepatol.37(6), 866–869 (2002).
   PubMed Web of Science ®Google Scholar
• Pramoolsinsap C, Poovorawan Y, Hirsch P, Busagorn N, Attamasirikul K. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann. Trop. Med. Parasitol.93(7), 745–751 (1999).
   PubMed Web of Science ®Google Scholar
• Vento S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J. Viral Hepat.7(Suppl. 1), 7–8 (2000).
   PubMedGoogle Scholar
• Shim M, Khaykis I, Park J, Bini EJ. Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology42(3), 688–695 (2005).
   PubMed Web of Science ®Google Scholar
• Deterding K, Tegtmeyer B, Cornberg M et al. Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. J. Hepatol.45(6), 770–778 (2006).
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Coppola N, Pisaturo M et al. Clinical and virological improvement of hepatitis B virus-related or hepatitis C virus-related chronic hepatitis with concomitant hepatitis A virus infection. Clin. Infect. Dis.42(11), 1536–1543 (2006).
   PubMed Web of Science ®Google Scholar
• Bradley DW, Maynard JE, McCaustland KA, Murphy BL, Cook EH, Ebert JW. Non-A, non-B hepatitis in chimpanzees: interference with acute hepatitis A virus and chronic hepatitis B virus infections. J. Med. Virol.11(3), 207–213 (1983).
   PubMed Web of Science ®Google Scholar
• Pramoolsinsap C, Attamasirul K, Busagorn N et al. Susceptibility to hepatitis A virus infection among chronic liver disease patients and healthy blood donors in Thailand. Southeast Asian J. Trop. Med. Public Health30(1), 91–95 (1999).
   PubMedGoogle Scholar
• Hamid SS, Atiq M, Shehzad F et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology36(2), 474–478 (2002).
   PubMed Web of Science ®Google Scholar
• Rambusch EG, Wedemeyer H, Tillmann HL, Heringlake S, Manns MP. Significance of coinfection with hepatitis G virus for chronic hepatitis C – a review of the literature. Z. Gastroenterol.36(1), 41–53 (1998).
   PubMedGoogle Scholar
• Myers RP, Thibault V, Poynard T. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. J. Viral Hepat.10(2), 103–110 (2003).
   PubMedGoogle Scholar
• Francesconi R, Giostra F, Ballardini G et al. Clinical implications of GBV-C/HGV infection in patients with “HCV-related” chronic hepatitis. J. Hepatol.26(6), 1165–1172 (1997).
   PubMed Web of Science ®Google Scholar
• Chu C, Hwang S, Luo J et al. Clinical, virological, immunological, and pathological significance of GB virus C/hepatitis G infection in patients with chronic hepatitis C. Hepatol. Res.19(3), 225–236 (2001).
   PubMedGoogle Scholar
• Yang JF, Dai CY, Chuang WL et al. Prevalence and clinical significance of HGV/GBV-C infection in patients with chronic hepatitis B or C. Jpn J. Infect. Dis.59(1), 25–30 (2006).
   PubMedGoogle Scholar
• Kaya S, Cicioglu Aridogan B, Demirci M. The prevalence of hepatitis G virus in patients with hepatitis B and C virus infections. Mikrobiyol. Bul.38(4), 421–427 (2004).
   PubMedGoogle Scholar
• Komatsu H, Fujisawa T, Inui A et al. GBV-C/HGV infection in children with chronic hepatitis C. J. Med. Virol.59(2), 154–159 (1999).
   PubMedGoogle Scholar
• Hardikar W, Moaven LD, Bowden DS, Locarnini SA, Smith AL. Hepatitis G: viroprevalence and seroconversion in a high-risk group of children. J. Viral Hepat.6(4), 337–341 (1999).
   PubMedGoogle Scholar
• Tacke M, Schmolke S, Schlueter V et al. Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors. Hepatology26(6), 1626–1633 (1997).
   PubMed Web of Science ®Google Scholar
• Yzebe D, Xueref S, Baratin D, Bouletreau A, Fabry J, Vanhems P. TT virus. A review of the literature. Panminerva Med.44(3), 167–177 (2002).
   Google Scholar
• Moen EM, Sagedal S, Bjoro K, Degre M, Opstad PK, Grinde B. Effect of immune modulation on TT virus (TTV) and TTV-like-mini-virus (TLMV) viremia. J. Med. Virol.70(1), 177–182 (2003).
   PubMedGoogle Scholar
• Christensen JK, Eugen-Olsen J, Slrensen M et al. Prevalence and prognostic significance of infection with TT virus in patients infected with human immunodeficiency virus. J. Infect. Dis.181(5), 1796–1799 (2000).
   PubMed Web of Science ®Google Scholar
• Shang D, Lin YH, Rigopoulou I, Chen B, Alexander GJ, Allain JP. Detection of TT virus DNA in patients with liver disease and recipients of liver transplant. J. Med. Virol.61(4), 455–461 (2000).
   PubMed Web of Science ®Google Scholar
• Shibayama T, Masuda G, Ajisawa A et al. Inverse relationship between the titre of TT virus DNA and the CD4 cell count in patients infected with HIV. AIDS15(5), 563–570 (2001).
   PubMed Web of Science ®Google Scholar
• Touinssi M, Gallian P, Biagini P et al. TT virus infection: prevalence of elevated viraemia and arguments for the immune control of viral load. J. Clin. Virol.21(2), 135–141 (2001).
   PubMed Web of Science ®Google Scholar
• Par A, Takacs M, Brojnas J et al. Co-infections with hepatitis G and TT virus in patients with chronic hepatitis C in Hungary. Acta Microbiol. Immunol. Hung.51(4), 437–447 (2004).
   PubMedGoogle Scholar
• Al-Moslih MI, Abuodeh RO, Hu YW. Detection and genotyping of TT virus in healthy and subjects with HBV or HCV in different populations in the United Arab Emirates. J. Med. Virol.72(3), 502–508 (2004).
   PubMedGoogle Scholar
• Ali S, van Pelt JF, Verslype C, Nevens F, Fevery J, Yap SH. TT virus infection in acute and chronic liver diseases and in patients regularly receiving blood products in Belgium. Acta Gastroenterol. Belg.67(2), 161–165 (2004).
   PubMedGoogle Scholar
• Asselah T, Boudjema H, Francoz C et al. Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management. Gastroenterol. Clin. Biol.30(11), 1281–1295 (2006).
   PubMedGoogle Scholar
• Tokita H, Murai S, Kamitsukasa H et al. High TT virus load as an independent factor associated with the occurrence of hepatocellular carcinoma among patients with hepatitis C virus-related chronic liver disease. J. Med. Virol.67(4), 501–509 (2002).
   PubMedGoogle Scholar
• Kamal SM, Bianchi L, Al Tawil A et al. Specific cellular immune response and cytokine patterns in patients coinfected with hepatitis C virus and Schistosoma mansoni. J. Infect. Dis.184(8), 972–982 (2001).
   PubMed Web of Science ®Google Scholar
• Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol.162(2), 931–938 (1999).
   PubMed Web of Science ®Google Scholar
• Wong V, Wreghitt TG, Alexander GJ. Prospective study of hepatitis B vaccination in patients with chronic hepatitis C. Br. Med. J.312(7042), 1336–1337 (1996).
   PubMedGoogle Scholar
• Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J. Med. Virol.78(2), 169–177 (2006).
   PubMed Web of Science ®Google Scholar
• Lee SD, Chan CY, Yu MI, Lu RH, Chang FY, Lo KJ. Hepatitis B vaccination in patients with chronic hepatitis C. J. Med. Virol.59(4), 463–468 (1999).
   PubMedGoogle Scholar
• Wiedmann M, Liebert UG, Oesen U et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology31(1), 230–234 (2000).
   PubMed Web of Science ®Google Scholar
• Idilman R, De MN, Colantoni A, Nadir A, Van Thiel DH. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am. J. Gastroenterol.97(2), 435–439 (2002).
   PubMed Web of Science ®Google Scholar
• Leroy V, Bourliere M, Durand M et al. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case–control study. Eur. J. Gastroenterol. Hepatol.14(5), 485–489 (2002).
   PubMed Web of Science ®Google Scholar
• Elefsiniotis IS, Vezali E, Kamposioras K et al. Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment. World J. Gastroenterol.12(27), 4420–4424 (2006).
   PubMed Web of Science ®Google Scholar
• Mattos AA, Gomes EB, Tovo CV, Alexandre CO, Remiao JO. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq. Gastroenterol.41(3), 180–184 (2004).
   PubMedGoogle Scholar
• Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am. J. Gastroenterol.97(2), 427–434 (2002).
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Iwarson S, McMahon BJ et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology27(3), 881–886 (1998).
   PubMedGoogle Scholar
• Lee SD, Chan CY, Yu MI et al. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J. Med. Virol.52(2), 215–218 (1997).
   PubMedGoogle Scholar
• Majda-Stanislawska E, Bednarek M, Kuydowicz J. Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease. Pediatr. Infect. Dis. J.23(6), 571–574 (2004).
   PubMed Web of Science ®Google Scholar
• Kallinowski B, Jilg W, Buchholz L, Stremmel W, Engler S. Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Z. Gastroenterol.41(10), 983–990 (2003).
   PubMed Web of Science ®Google Scholar
• Duchini A, Viernes ME, Nyberg LM, Hendry RM, Pockros PJ. Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch. Intern. Med.160(1), 113–115 (2000).
   PubMedGoogle Scholar
• Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl.7(4), 311–313 (2001).
   PubMedGoogle Scholar
• De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology20(5), 1225–1230 (1994).
   PubMedGoogle Scholar
• Gaeta GB, Stornaiuolo G, Precone DF, Amendola A, Zanetti AR. Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine20(Suppl. 5), B33–B35 (2002).
   PubMed Web of Science ®Google Scholar
• Navasa M, Rodes J. Bacterial infections in cirrhosis. Liver Int.24(4), 277–280 (2004).
   PubMed Web of Science ®Google Scholar
• Ghassemi S, Garcia-Tsao G. Prevention and treatment of infections in patients with cirrhosis. Best Pract. Res. Clin. Gastroenterol.21(1), 77–93 (2007).
   PubMed Web of Science ®Google Scholar
• Bowen DG, Zen M, Holz L, Davis T, McCaughan GW, Bertolino P. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. Clin. Invest.114(5), 701–712 (2004).
   Google Scholar
• Warren A, Le Couteur DG, Fraser R, Bowen DG, McCaughan GW, Bertolino P. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology44(5), 1182–1190 (2006).
   PubMed Web of Science ®Google Scholar
• Carithers RL Jr, Sugano D, Bayliss M. Health assessment for chronic HCV infection: results of quality of life. Dig. Dis. Sci.41(Suppl. 12), 75S–80S (1996).
   PubMed Web of Science ®Google Scholar
• Strauss E, Dias Teixeira MC. Quality of life in hepatitis C. Liver Int.26(7), 755–765 (2006).
   PubMedGoogle Scholar
• Arguedas MR, McGuire BM, Fallon MB. Implementation of vaccination in patients with cirrhosis. Dig. Dis. Sci.47(2), 384–387 (2002).
   PubMedGoogle Scholar
• Potthoff A, Sarhaddar J, Wiegand J et al. Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. Hepatol. Res.31(1), 18–23 (2005).
   PubMedGoogle Scholar